Publications
Gilligan T, Bohlke K, Alpert AB, Coyle N, Harichand-Herdt S, Lathan CS, Razis E, Rivera K, Sanft T, Seigel C, Times M, Chou CL. Patient-Clinician Communication: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41805420
Jacob S, Mayer EL, Kacik N, Storniolo AM, Isaacs C, Mayer I, Stearns V, Nanda R, Nangia J, Chien AJ, Moasser M, Melisko M, Wabl C, Muzikansky A, Geradts J, Dillon DA, Park BH, Krop I, Wolff AC, Kochupurakkal B, Shapiro GI, Rugo HS. TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer. ESMO open. 2026. PMID: 41812623
Neyazi N, Chakravarty D, Xia F, Hawes MR, Max W, Kushel M, Vijayaraghavan M. Attitudes toward tobacco-free and cannabis-free policies among residents in permanent supportive housing who use tobacco, cannabis, and other substances. Addictive behaviors reports. 2026. PMID: 41858814
Graham AJ, Khoo MWL, Srivastava V, Viragova S, Kim H, Parekh K, Hennick KM, Bird M, Goldhammer N, Yu JZ, Hu G, Brinkley NT, Pardo L, Amaya JS, Morley CD, Chadha N, Lebel P, Kumar S, Rosenbluth JM, Nowakowski TJ, Chaudhuri O, Klein O, Gómez-Sjöberg R, Gartner ZJ. Stress-relaxing granular bioprinting materials enable complex and uniform organoid self-organization. Nature materials. 2026. PMID: 41807773
Vijayaraghavan M, Williams A, Bonniot C, Cheng C, Clark B, Safier J, Satterfield J, Pamatmat M, Schroeder SA. State Leadership Academies to Reduce Tobacco Use Prevalence in the United States: Four Case Studies of Early State Adopters of Tobacco Treatment and Policy. Public health reports (Washington, D.C. : 1974). 2026. PMID: 41797633
Datta D, Nzau M. Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery. 2026. PMID: 41803275
Al-Toma D, Kemna R, Ali M, Zwart K, Zeeuw MJ, Stehouwer BL, de Jong PA, Kurk S, Braat MNGJA, Lagendijk JJW, May AM, Koopman M, Verpalen IM, Swijnenburg RJ, Punt CJA, Kazemier G, Bol GM. Tumor burden in metastatic colorectal cancer quantified using deep learning models: Prognostic value and maintenance treatment benefit in the CAIRO3 trial. European journal of cancer (Oxford, England : 1990). 2026. PMID: 41819026
Nadine Goldhammer, Marin Bont, Shruti Warhadpande, Michael Choi, Jose Cedano, Heather Greenwood, Julia Ye, Christopher Schwartz, Michael Alvarado, Cheryl Ewing, Karen Goodwin, Rita Mukhtar, Jasmine Wong, Shoko Abe, Julia Chandler, Jordan Jackson, Olufunmilayo Olopade, Michael Campbell, Allison Lam, Chaelee Park, Anna Vertido, Laura van 't Veer, Nola Hylton, Laura Esserman, Jennifer Rosenbluth. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue bioRxiv. 2026. PMID:
Corona M, García-Vicente R, Saez-Marin AJ, Ancos-Pintado R, Rodríguez-Garcia A, Arroyo A, Blanco A, Chari A, Martin T, Wolf J, Rey-Bua B, Mateos MV, Kortüm KM, Riedhammer C, Tamariz-Amador LE, Valencia E, Rodríguez-Otero P, San Miguel J, Ibarra G, Oriol A, Cedena MT, López-Muñoz N, Alonso R, Calbacho M, Sanchez-Pina JM, Linares M, Martínez-López J. Antibiotic-associated dysbiosis and bispecific antibody outcomes in multiple myeloma. Journal for immunotherapy of cancer. 2026. PMID: 41791791
Jhaveri K, Bidard FC, Kalinsky K, Neven P, Rugo HS, Tolaney SM, Litchfield LM, von Laue CC, Traore S, Sapunar F, Li Y, O'Shaughnessy J. Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials. ESMO open. 2026. PMID: 41785668
Kim J, Munster PN. Cracks in the Estrogen Carcinogenesis of Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41785447
Goldhammer N, Bont M, Warhadpande S, Choi M, Cedano J, Greenwood H, Ye J, Schwartz CJ, Alvarado M, Ewing C, Goodwin K, Mukhtar RA, Wong J, Abe SE, Chandler J, Jackson J, Olopade OI, Campbell MJ, Lam A, Park C, Vertido A, van 't Veer LJ, Hylton N, Esserman LJ, Rosenbluth JM. Hormone signaling and immune programs define differential endocrine responsiveness in high-risk breast tissue. bioRxiv : the preprint server for biology. 2026. PMID: 41867809
Slovin S, Gao X, Wei XX, Oh DY, McKay RR, Falchook G, Hussain A, McKean M, Wibmer A, Ho A, Eskew JD, Belani R, Coronella J, Haag S, Martin CE, McCaigue J, Mendoza J, Murphy A, Namini H, Spear MA, Shedlock DJ, Dorff TB. Phase 1 Trial of P-PSMA-101 CAR-T Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC). Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41779004
Bivona TG, Yanai I, Calabrò F, Mechta-Grigoriou F, Corleone G, Di Martile M, Tocci A, Tocci P, Vaccarella S, Ferriero MC, Alimonti A, Ruppin E, Nisticò P, Bagnato A, Blandino G. Challenges and advances in drug resistance and tolerance in cancer. Journal of experimental & clinical cancer research : CR. 2026. PMID: 41776655
Chrostek MR, Robinson J, Krishnan R, Yu EY, Nordquist LT, Vandross AL, Salkeni MA, Schehr J, Mannino M, Hintz A, Caceres J, Vatani M, Emamekhoo H, Nelson P, Markey C, Coates E, Breitmeyer J, Fong L, De Bono JS, Lang JM, Zhao SG. Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534. Investigational new drugs. 2026. PMID: 41774321
Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N, Saji S, Miyoshi Y, Bardia A, Harbeck N, Haiderali A, Fan L, Mejia JA, Karantza V, Llombart-Cussac A. KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41405563
Wan J, Saatcioglu HD, Ellis H, Aguado-Fraile E, Xu Q, Kondo H, Manguso RT, Gritti I, Norden BL, Noble C, Corcoran RB, Lubner SJ, Javle M, Abou-Alfa GK, Cleary JM, Kelley RK, Borad MJ, Macarulla T, Oh DY, Daigle S, Gliser C, Pandya S, Choe S, Tron AE, Bardeesy N. MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41460204
Leonhardt CS, Adham M, Bazarbashi S, Ben-Aharon I, Beets-Tan RGH, Boggi U, Brunner TB, Cellini F, Chiti A, Daamen L, De Bari B, De Dosso S, Ducreux M, Eng C, Falconi M, Ferrone CR, Frigerio I, Garajova I, Gerum S, Ghadimi M, Gruenberger T, Hammel P, Haustermans K, Hawkins M, He J, Heerkens HD, Huguet F, Intven MPW, Klaiber U, Kroese TE, Laurent-Puig P, Lordick F, Ludmir EB, Macarulla T, Matzinger O, Morganti AG, Mukherjee S, O'Reilly EM, Park JO, Papamichael D, Pfeiffer P, Ramia JM, Roeder F, Ruiz-García E, Satoi S, Scorsetti M, Schneider M, Seufferlein T, Serrablo A, Shrikhande SV, Smyth EC, Svrcek M, Takaori K, Tempero MA, Tissera NS, Tie J, Torres OJM, Turpin A, Van Cutsem E, Versteijne E, Vivaldi C, Wainberg ZA, Weichselbaum RR, Weitz J, Wolfgang CL, Prager GW, Strobel O. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. The Lancet. Oncology. 2026. PMID: 41785904
Aggarwal R, Bhatt DL. The potential of artificial intelligence in clinical trials. European journal of clinical investigation. 2026. PMID: 41761496
Chan SL, Yau T, Kelley RK, Finn RS, Yoo C, Furuse J, Ren Z, Klümpen HJ, Ozaka M, Pelzer U, Arslan C, Park JO, Edeline J, Valle JW, Ueno M, Vogel A, Starkopf L, Malhotra U, Siegel AB, Qin S. Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study. Cancer Research Communications. 2026. PMID: 41757470